The objective of this study was to evaluate whether treatment with meglumine antimoniate could induce pancreatitis in dogs with leishmaniosis, on the basis of clinical signs, canine-specific quantitative pancreatic lipase immunoreactivity (cPLI) serum concentration, and ultrasonographic abnormalities. The gene discussed is PNLIP; the disease is pancreatitis.